Basel-based CGC Genomics has raised €1.7 million in pre-Seed funding to innovate the interpretation of cancer genome data with its GenAI platform Qnomx, bringing to market their regulatory-grade generative AI solution for clinical decision support in oncology.
Backers include Heal Capital, Becker Ventures, Springboard Health Angels, Superangels, and better ventures – represented by business angels Christoph Behn, Nicolas Weber, and Helmut Deschauer.
“With Qnomx, we are building regulatory-compliant GenAI – enabling more precise therapies with less burden on medical professionals,” says James Creeden, MD PhD, Co-CEO of CGC Genomics and former Chief Medical Officer at Roche & Foundation Medicine.
Founded in 2023 by Dr Joerg Hoelzing, Dr James Creeden, MD PhD, and Marcus Olivecrona, CGC Genomics specialise in the regulated application of generative AI in oncology. Its platform Qnomx is developing the “world’s first regulatory-grade GenAI solution for interpreting cancer genome data” – with the goal of making more precise therapies faster and more widely available.
CGC Genomics aims to launch Qnomx as the first generative AI solution in cancer diagnostics with regulatory approval – compliant with IVDR, MDR, and the European AI Act. The platform is being developed under an ISO 13485-certified quality management system and offers a transparent, auditable alternative to unregulated tools like ChatGPT, which are currently being used in some clinical settings.
“With Qnomx, we’re supporting visionary founders building the AI infrastructure for the future of precision medicine. Qnomx impresses with an experienced team and a groundbreaking approach to one of the field’s core challenges: making genomic data truly actionable. We’re confident they will set a new standard for the safe use of generative AI in clinical diagnostics and therapy,” says Christian Lautner, Founding Managing Partner of Heal Capital.
Cancer cases are rising globally – according to data provided to EU-Startups, in 2022 alone, over 20 million new cases were diagnosed. Targeted therapy increasingly relies on molecular tumor analysis using Next Generation Sequencing (NGS). However, only 20–30% of patients who should receive sequencing according to clinical guidelines actually undergo such analysis. The main reason: around 80% of oncologists report that today’s NGS reports are too complex to quickly and confidently make treatment decisions. Interpreting them requires specialised knowledge and is time-consuming – a significant barrier in daily clinical practice.
This is where Qnomx looks to come in. The AI-powered platform processes the results of NGS analysis (i.e., the final report from tertiary analysis), translates them into clear, clinically relevant summaries – reportedly saving time, reducing costs, and minimising interpretation errors.
“We’re excited to announce our collaboration with CGC Genomics. As one of Bavaria’s leading laboratory medicine companies, with over 650 employees across 12 locations, we are committed to continuous innovation to provide our healthcare partners with top-tier diagnostics and streamlined processes. Based on our expertise in molecular pathology and genetic testing, we see significant potential in CGC Genomics’ Qnomx platform to further optimize the interpretation of complex genomic data.
“This partnership allows us to increase the efficiency and quality of our NGS process and make a valuable contribution to precision medicine. We are confident this collaboration will advance diagnostics and look forward to the next steps with CGC Genomics,” says Marc Becker, Managing Director of Labor Becker MVZ eGbR.
Internal use of the tool has shown significant efficiency gains, now being validated in pilot projects with Labor Becker and the OnkoMedeor Group. Instead of up to two hours of manual analysis, Qnomx claims to deliver a concise clinical summary of key findings in minutes – in the local language and always with a “human in the loop.”
“Diagnostics can scale – interpretation cannot. That’s exactly what we’re changing with Qnomx,” explains Dr Joerg Hoelzing, Co-CEO of CGC Genomics.
“Artificial intelligence will fundamentally transform healthcare – but only if it is regulated, explainable, and responsibly applied. That is exactly what CGC Genomics delivers: a team with deep medical expertise, a clear vision, and a product that is safe for patients, scalable, and economically viable. Qnomx democratises access to precision cancer therapy – bringing cutting-edge medicine to where expertise is currently lacking,” says Tina Dreimann, Founder and managing director of better ventures.
Read the orginal article: https://www.eu-startups.com/2025/04/swiss-healthtech-startups-cgc-genomics-raises-e1-7-million-for-regulated-genai-platform/
